Navigation Links
NIAID strengthens and expands Vaccine and Treatment Evaluation Units
Date:11/6/2007

The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, has awarded eight contracts to strengthen and expand its nationwide group of institutions conducting clinical trials of promising candidate vaccines and therapies for infectious diseases. In addition to increasing the number of sites from seven to eight, NIAID expects the Vaccine and Treatment Evaluation Units (VTEUs) to carry out more clinical trials in larger populations and to safely test vaccines in specific vulnerable populations, such as infants and the elderly. Moreover, all the VTEUs will have inpatient beds for isolating volunteers who participate in the testing of vaccines containing weakened versions of live microbes, making it easier to conduct such trials quickly.

Each VTEU will receive approximately $23.7 million over seven years. The combined capabilities of these research facilitieslocated in Atlanta, Baltimore, Cincinnati, Houston, Iowa City, Nashville, Seattle and St. Louiswill enhance NIAIDs ability to direct clinical research to quickly respond to emerging public health needs.

In more than four decades of research, the VTEUs have conducted hundreds of clinical trials of investigational vaccines and therapeutics for a variety of infectious diseases of public health concern, and many of these trials have contributed to the licensure of products, says NIAID Director Anthony S. Fauci, M.D. We expect this success to continue, as each VTEU has exceptional expertise and experience in vaccinology and an impressive capacity to recruit volunteers from diverse populations in its community.

Established in 1962, the VTEUs are a national resource for vaccine development. VTEU investigators have tested and advanced vaccines for many diseases, including influenza, pneumonia, whooping cough, Haemophilus influenzae infection, cytomegalovirus infection, malaria, smallpox, anthrax and tularemia. Childhood vaccines and combination vaccinesthe delivery of several vaccines through one inoculationhave been and remain an important part of the VTEUs research goals. The first trial of an edible vaccine was conducted by VTEU researchers, and other novel vaccine delivery systems have been extensively tested by this select group of medical research facilities. For example, one VTEU demonstrated that consuming genetically engineered potatoes could stimulate an immune response against Escherichia coli in humans, and six VTEUs enrolled young children in a successful Phase III trial of FluMist, an influenza vaccine delivered through a nasal spray.

An important strength of the VTEUs is their ability to enroll large numbers of volunteers into trials rapidly and vaccinate them in a manner that is safe, effective and quick to yield results. This rapid-response capability is especially important for testing vaccines designed to counteract emerging public health concerns. For example, the VTEUs conducted multiple studies in 2005 and 2006 of a vaccine for a strain of H5N1 avian influenza virus to determine the most effective dose. Those studies led to the licensure of the first vaccine approved by the U.S. Food and Drug Administration (FDA) against an H5N1 influenza virus. The units also swiftly initiated a large-scale trial to evaluate the seasonal influenza vaccine Fluarix for use in healthy adults in the United States. The trial demonstrated the vaccines safety and ability to generate an immune response and ultimately led to its expedited approval by FDA in August 2005less than a year after the trial began. This approval helped reduce the impact of future delays or shortages of seasonal influenza vaccines in the United States.

The selected VTEU sites and principal investigators (PIs) are as follows.

Baylor College of Medicine
Houston, Texas
PI: Wendy A. Keitel, M.D.

Children's Hospital Medical Center
Cincinnati, Ohio
PI: David I. Bernstein, M.D., M.A.

Emory University
Atlanta, Georgia
PI: Mark J. Mulligan, M.D.

Group Health Cooperative
Seattle, Washington
PI: Lisa A. Jackson, M.D., M.P.H.

Saint Louis University
St. Louis, Missouri
PI: Robert B. Belshe, M.D.

University of Iowa
Iowa City, Iowa
PI: Patricia L. Winokur, M.D.

University of Maryland
Baltimore, Maryland
PI: Karen L. Kotloff, M.D.

Vanderbilt University
Nashville, Tennessee
PI: Kathryn M. Edwards, M.D.


'/>"/>

Contact: Laura Sivitz
sivitzl@niaid.nih.gov
301-402-1663
NIH/National Institute of Allergy and Infectious Diseases
Source:Eurekalert

Related medicine news :

1. NIAID funds $51M contract to create comprehensive model of immune responses
2. Kenyan malaria success strengthens call for free insecticide-treated nets for all
3. International study strengthens case for daily calcium pill
4. Wachovia Strengthens Its Healthcare Industry Receivables and Cash Management Capabilities
5. Essilor Strengthens its Polarized Lens Distribution Network With the Acquisition of KBco
6. Publicis Groupe Strengthens its Leadership in Digital and Integrated Healthcare Communications in Italy
7. Longaberger Expands Horizon of Hope Campaign to Build Support for American Cancer Societys Breast Cancer Initiatives
8. Rohm and Haas Expands in India
9. Concentra Expands Horizon Air Employee Health Program With On-Site Clinic
10. Regional Center of Orange County Expands Family Support Resources to Meet Growing Needs
11. Maimonides Expands Circulation of Physicians Practice Journal to Staten Island Doctors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/16/2017)... (PRWEB) , ... August 16, 2017 , ... ... Endoscopes states: “Drying the endoscope after every reprocessing cycle, both between patient procedures ... transmission and nosocomial infections. Drying is as important to the prevention of disease ...
(Date:8/16/2017)... ... August 16, 2017 , ... Harbor Retirement Associates ... announced today that two of their associates were recognized with individual “Best of ... living communities in Florida. The awards were announced at the 5th Annual 2017 ...
(Date:8/16/2017)... Park (PRWEB) , ... August 16, 2017 , ... TopConsumerReviews.com ... offering Lab Testing . , The healthcare industry in the United States has ... Gone are the days of needing to have a doctor’s order to get a ...
(Date:8/16/2017)... Birmingham, Clarkston, Lake Orion, Rochester, Michigan (PRWEB) , ... ... ... Michigan, will now offer treatment options to patients suffering from chronic pelvic pain. ... diagnosis and treatment of various pelvic pain disorders including endometriosis, menorrhagia (abnormal heavy ...
(Date:8/16/2017)... ... August 16, 2017 , ... ... of high-quality anti-aging skincare solutions, recently announced the launch of two new skincare ... affordable, yet effective alternative to expensive plastic surgery or in-patient cosmetic dermatological procedures. ...
Breaking Medicine News(10 mins):
(Date:8/10/2017)... LAKEWOOD, Colo. , Aug. 10, 2017  Physical Rehabilitation ... Therapy, located in Lakewood, Colorado . The ... Jeff Lipkin , PT, DPT with his staff of ... the University of Pittsburgh and brings over 10 years of ... Belmar PT marks the 10th PRN clinic ...
(Date:8/7/2017)... , Aug. 7, 2017 Diplomat Pharmacy, Inc. (NYSE: ... Joel Saban as president, effective Aug. 7, 2017. ... has decided to pursue other interests and will serve as ... tenure, Paul has served us in multiple leadership roles since ... in Jun. 2015 and has provided decisive, strategic leadership which ...
(Date:8/3/2017)... -- Opioid addiction and other drugs of abuse, blood poisoning ... outcomes, were problems taken on directly as laboratory professionals, ... them, met this week. This according to Kalorama Information. ... abuse, procalcitonin and acute kidney injury were key focuses ... in San Diego, CA.  Mechanisms ...
Breaking Medicine Technology: